Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
OTC:IDXG
Price:
1.42 USD
-3.4%
Market Closed
Updated:
Jun 11, 2024
Interpace Biosciences Inc
Total Current Liabilities
|
Interpace Biosciences Inc
Total Current Liabilities Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Interpace Biosciences Inc
OTC:IDXG
|
Total Current Liabilities
$19m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-4%
|
|
|
DaVita Inc
NYSE:DVA
|
Total Current Liabilities
$2.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
0%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Total Current Liabilities
$2.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
CVS Health Corp
NYSE:CVS
|
Total Current Liabilities
$83.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
|
Cigna Corp
NYSE:CI
|
Total Current Liabilities
$52B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
See Also
What is Interpace Biosciences Inc's Total Current Liabilities?
Total Current Liabilities
19m
USD
19m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Total Current Liabilities amounts to 19m USD.
What is Interpace Biosciences Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-4%
-4%
Over the last year, the Total Current Liabilities growth was 36%. The average annual Total Current Liabilities growth rates for Interpace Biosciences Inc have been -3% over the past three years , 14% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
